Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2024 09:07 ET | Source: Amarna Therapeutics

Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease

Grasse, France and Leiden, the Netherlands – 11 December 2024 – Phenocell SAS (part of Axol Bioscience) a leading provider of stem cell-derived models and services, and Amarna Therapeutics, a...
October 31, 2024 09:00 ET | Source: e-therapeutics plc

e-therapeutics Announces Business Updates and Interim Results

LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
October 17, 2024 08:56 ET | Source: SNS Insider pvt ltd

Dry Age-Related Macular Degeneration Market to Reach USD 10.57 Billion by 2032 with 9.1% CAGR – SNS Insider

Pune, Oct. 17, 2024 (GLOBE NEWSWIRE) -- SNS Insider reports that the Dry Age-related Macular Degeneration Market, valued at USD 4.83 billion in 2023, is expected to reach USD 10.57 billion by the...
December 13, 2023 07:30 ET | Source: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
December 01, 2022 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting...
April 25, 2022 16:01 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
February 10, 2022 13:00 ET | Source: DelveInsight Business Research LLP

Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry Age-Related Macular...
October 19, 2021 07:00 ET | Source: Retrotope

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...
February 11, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...